chanoclavine-I dehydrogenase easD
Top stories
Latest
- 19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASDprnewswire.com · 2026-10-02 04:35 UTC · story
- Novo's investigational obesity and diabetes drug CagriSema reduces 'food noise' and shows benefits in organ and bone health – EASD 2026 | Company Announcementinvestegate.co.uk · 2026-09-30 12:52 UTC · story